Immunological Defects in Chronic Pulmonary Aspergillosis

Immunological Defects in Chronic Pulmonary Aspergillosis - Immunological Defects in CPA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48258

Enrollment

Registered

2019-06-17

Start date

2019-08-22

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pulmonary Aspergillosis (CPA)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Adult patient (> 18 years of age) 2. Patient is able to give written informed consent 3. Diagnosis of CPA is established in the patient based on the diagnostic criteria according to the ESCMID/ERS guidelines

Exclusion criteria

Exclusion criteria: Known active infection with HIV

Design outcomes

Primary

Measure	Time frame
The main study parameters / endpoints are the differences between patients with CPA and patients with COPD without CPA with regard to: 1. Cytokine production by peripheral blood mononuclear cells (PBMCs) in response to different stimuli 2. Aspergillus fumigatus conidia killing capacity of polymorphonuclear neutrophils (PMNs) 3. Single nucleotide polymorphisms (SNPs) in relevant genes involved in immune recognition and / or immune response 4. RNA expression of relevant genes involved in immune recognition and / or response in PBMCs 5. Metabolome pathways in macrophages (derived from CD14+ monocytes from peripheral blood) 6. LC3-associated phagocytosis (LAP) by CD14+ monocytes Depending on interim results, the investigators would like to retain the possibility to decide to change the exact stimuli and read-out parameters during the course of this research project, not leading to any changes in the amount of blood drawn or burden in any other way for the patients. To be able to correlate experimental results to clinical characteristics, several clinical characteristics will be collected about the patients in coded form (coded according to patient number in the electronic patient file), including: - Age - Sex - CPA subgroup (aspergilloma, Aspergillus nodule, CCPA, CFPA) - Medication used - HIV status, if known	—

Measure

Time frame

The main study parameters / endpoints are the differences between patients with CPA and patients with COPD without CPA with regard to: 1. Cytokine production by peripheral blood mononuclear cells (PBMCs) in response to different stimuli 2. Aspergillus fumigatus conidia killing capacity of polymorphonuclear neutrophils (PMNs) 3. Single nucleotide polymorphisms (SNPs) in relevant genes involved in immune recognition and / or immune response 4. RNA expression of relevant genes involved in immune recognition and / or response in PBMCs 5. Metabolome pathways in macrophages (derived from CD14+ monocytes from peripheral blood) 6. LC3-associated phagocytosis (LAP) by CD14+ monocytes Depending on interim results, the investigators would like to retain the possibility to decide to change the exact stimuli and read-out parameters during the course of this research project, not leading to any changes in the amount of blood drawn or burden in any other way for the patients. To be able to correlate experimental results to clinical characteristics, several clinical characteristics will be collected about the patients in coded form (coded according to patient number in the electronic patient file), including: - Age - Sex - CPA subgroup (aspergilloma, Aspergillus nodule, CCPA, CFPA) - Medication used - HIV status, if known

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results